Skip to main content

Cadrenal Therapeutics, Inc.

corporate_fare Company Profile

Cadrenal Therapeutics, Inc.

CVKD·NASDAQ·Life Sciences·CIK 0001937993

The Company is a late-stage biopharmaceutical company focused on developing new treatments for serious immune and thrombotic conditions. Following the acquisition of a 12-lipoxygenase ("12-LOX") platform of assets in December 2025, the company shifted its main strategic focus to developing CAD-1005 for immune-mediated and thrombotic disorders. The company's primary product candidate, CAD-1005, is a selective 12-LOX inhibitor designed to treat heparin-induced thrombocytopenia ("HIT"), a severe immune-mediated thrombotic disorder. CAD-1005 has been tested in a blinded, placebo-controlled Phase 2 clinical trial involving 24 patients, and in Phase 1 clinical trials with over 100 patients. On March 26, 2026, the company completed its End-of-Phase 2 ("EOP2") meeting with the FDA, clarifying a potential path for its planned Phase 3 pivotal trial of CAD-1005 in HIT patients. CAD-1005 has received an orphan drug designation ("ODD") from the FDA for preventing thrombosis in HIT patients, an FDA Fast Track designation for treating and preventing HIT, and an orphan designation from the EMA for treating platelet-activating factor 4 disorders. The company's pipeline also includes two other clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist ("VKA") intended as a warfarin replacement for patients with complex needs, designed to prevent heart attacks, strokes, and deaths from blood clots in patients needing chronic anticoagulation. The focus for tecarfarin is for chronic use in patients with kidney dysfunction or left ventricular assist devices ("LVADs"), specifically designed to overcome metabolic factors that can make warfarin less reliable. Frunexian is a Phase 2-ready intravenous ("IV") Factor XIa inhibitor, intended for acute care settings where medical devices or artificial surfaces significantly activate coagulation.

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 39 items for CVKD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CVKD spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Cadrenal 10-Q: Going Concern Reiterated, Cash Runs to Q1 2027, Defective ATM Sales Ratified
  • Cadrenal Launches Formal Strategic Review, Hires Tungsten Advisors
  • Cadrenal Secures FDA Alignment on Phase 3 Endpoint for CAD-1005 in HIT
  • FDA Aligns on Phase 3 Endpoint for CAD-1005 in HIT, Clearing Path to Registration
  • Cadrenal Reports Q2 Loss, $4.2M Cash Runway to Q1 2027, Launches Partnering Process

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$13.24M
Diluted EPS
-$6.64
Op. Cash Flow
-$12.6M
Free Cash Flow
-$12.61M
Operating Income
-$13.46M
Cash & Equivalents
$4.01M
Debt / Equity
0.00×
Shares Outstanding
2.34M sh
Source: 10-K · filed 2026-03-31 · accession 0001213900-26-036946

Short Interest & Short Volume

3.48 days to cover

FINRA reported short interest of 230,655 shares in CVKD as of the October 30, 2026 settlement, a 18.0% decrease from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 51.1% of CVKD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)230,655 shares as of October 30, 2026
Change vs prior period▼ 18.0%
Days to cover3.48 at avg daily volume of 66,328
Daily short volume (FINRA facilities)51.1% of 111,897 shares on November 20, 2026
5-day average short volume56.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for CVKD, detected from its recent SEC filings · based on capital-structure filings through 2026-07-20.

ATM program1 shelf registration

Resale Registration of 2.94M Shares · Potential $6M in Additional Proceeds

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$1.61 -5.29% today
52-week range · as of 2026-11-16 $0.8163 – $12.5
Market cap
$7.01M
Volume
206.7K (1.5× avg)
3-mo avg 134.9K
Live data · 2026-11-22 12:43 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CVKD - Latest Insights

CVKD
Nov 16, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.40
Real-time Price: $1.61 info
Change: +$0.210 (+15%) info
Market Cap: $7.008M info
CVKD
Oct 07, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Updated Oct 7, 9:25 AM ET — Cadrenal's 8-K confirms the board authorized the strategic process and Tungsten Advisors as exclusive advisor; no deadline set.
Price at Filing: $1.10
Real-time Price: $1.61 info
Change: +$0.510 (+46%) info
Market Cap: $7.008M info
CVKD
Aug 31, 2026, 8:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.61 info
Change: +$0.110 (+7%) info
Market Cap: $7.008M info
CVKD
Aug 31, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $1.61 info
Change: -$0.020 (-1%) info
Market Cap: $7.008M info
CVKD
Aug 13, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.86
Real-time Price: $1.61 info
Change: -$0.250 (-13%) info
Market Cap: $7.008M info
CVKD
Aug 03, 2026, 5:12 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.96
Real-time Price: $1.61 info
Change: -$0.350 (-18%) info
Market Cap: $7.008M info
CVKD
Aug 03, 2026, 5:09 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.96
Real-time Price: $1.61 info
Change: -$0.350 (-18%) info
Market Cap: $7.008M info
CVKD
Aug 03, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.97
Real-time Price: $1.61 info
Change: -$0.360 (-18%) info
Market Cap: $7.008M info
CVKD
Jul 23, 2026, 5:22 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $2.03
Real-time Price: $1.61 info
Change: -$0.420 (-21%) info
Market Cap: $7.008M info
CVKD
Jul 21, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.20
Real-time Price: $1.61 info
Change: -$0.590 (-27%) info
Market Cap: $7.008M info
CVKD
Jul 20, 2026, 4:37 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $2.09
Real-time Price: $1.61 info
Change: -$0.480 (-23%) info
Market Cap: $7.008M info
CVKD
Jul 13, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $2.46
Real-time Price: $1.61 info
Change: -$0.850 (-35%) info
Market Cap: $7.008M info
CVKD
Jul 13, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.10
Real-time Price: $1.61 info
Change: -$1.49 (-48%) info
Market Cap: $7.008M info
CVKD
Jul 10, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.89
Real-time Price: $1.61 info
Change: -$1.28 (-44%) info
Market Cap: $7.008M info
CVKD
Jul 06, 2026, 7:19 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.27
Real-time Price: $1.61 info
Change: -$1.66 (-51%) info
Market Cap: $7.008M info
CVKD
Jul 01, 2026, 5:23 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.00
Real-time Price: $1.61 info
Change: -$1.39 (-46%) info
Market Cap: $7.008M info
CVKD
Jun 30, 2026, 8:00 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.34
Real-time Price: $1.61 info
Change: -$1.73 (-52%) info
Market Cap: $7.008M info
CVKD
Jun 29, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $1.61 info
Change: -$1.41 (-47%) info
Market Cap: $7.008M info
CVKD
Jun 29, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $1.61 info
Change: -$1.41 (-47%) info
Market Cap: $7.008M info
CVKD
Jun 18, 2026, 9:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.14
Real-time Price: $1.61 info
Change: -$1.53 (-49%) info
Market Cap: $7.008M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets